Home » Newsletters » BioWorld Science

BioWorld Science

May 29, 2013

View Archived Issues

The discovery and preclinical validation of a potent antitumor peptide vaccine

ONO-6950 shows potential as a novel therapeutic option for bronchial asthma

Researchers from Kineta present novel broad-spectrum antiviral compounds

MedImmune presents results for MEDI-565 and MEDI-575

Medigene and SynCore extend agreement for anticancer candidate

FDA tests potential universal influenza vaccine

Analysis of LRG glycosylation allows for improved diagnostic accuracy in HF

Researchers present preclinical results for leukadherin-1

New TRPV1 ligands patented by Grunenthal

New bispecific antibody fusion proteins disclosed by UCB

Genentech presents new series of BTK inhibitors

Merck & Co. discloses new mGlu2 receptor antagonists

Researchers at Theravance design novel HCV NS5A inhibitors

Cellmid completes acquisition of Advangen

Phase I/IIa study of dendritic cell-based vaccine for AML meets endpoints

Arrowhead Research plans phase I study of ARC-520 for chronic HBV infection

Cellular Dynamics licenses rights to develop cardiomyocyte progenitors for therapeutic use

FDA grants breakthrough therapy designation to Alexion's asfotase alfa

Stribild receives European approval

Nouriast set to launch in Japan

Pharmstandard increases stake in Biolek

FDA issues complete response letter for Valeant's efinaconazole

Omeros plans European phase I study of OMS-721 for atypical hemolytic uremic syndrome

Aslan reports positive data from phase II ALSAN-001 study

First clinical study of Bionor Pharma's HIV vaccine candidate Vacc-C5 completes enrollment

Cenix BioScience to identify predictive biomarkers for Debiopharm's oncology candidates

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
Chengdu Mfs Pharma synthesizes new compounds for pain
BioWorld Science
Chengdu Mfs Pharma Co. Ltd. has prepared and tested compounds for the potential treatment of pain, sleep disorder and status epilepticus epilepsy as well as for...